



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2008

Amelogenin in cranio-facial development: the tooth as a model to study the role of amelogenin during embryogenesis

Gruenbaum-Cohen, Y ; Tucker, A S ; Haze, A ; Shilo, D ; Taylor, A L ; Shay, B ; Sharpe, P T ; Mitsiadis, T A ; Ornoy, A ; Blumenfeld, A ; Deutsch, D

Abstract: The amelogenins comprise 90% of the developing extracellular enamel matrix proteins and play a major role in the biomineralization and structural organization of enamel. Amelogenins were also detected, in smaller amounts, in postnatal calcifying mesenchymal tissues, and in several nonmineralizing tissues including brain. Low molecular mass amelogenin isoforms were suggested to have signaling activity; to produce ectopically chondrogenic and osteogenic-like tissue and to affect mouse tooth germ differentiation in vitro. Recently, some amelogenin isoforms were found to bind to the cell surface receptors; LAMP-1, LAMP-2 and CD63, and subsequently localize to the perinuclear region of the cell. The recombinant amelogenin protein (rHAM(+)) alone brought about regeneration of the tooth supporting tissues: cementum, periodontal ligament and alveolar bone, in the dog model, through recruitment of progenitor cells and mesenchymal stem cells. We show that amelogenin is expressed in various tissues of the developing mouse embryonic cranio-facial complex such as brain, eye, ganglia, peripheral nerve trunks, cartilage and bone, and is already expressed at E10.5 in the brain and eye, long before the initiation of tooth formation. Amelogenin protein expression was detected in the tooth germ (dental lamina) already at E13.5, much earlier than previously reported (E19). Application of amelogenin (rHAM(+)) beads together with DiI, on E13.5 and E14.5 embryonic mandibular mesenchyme and on embryonic tooth germ, revealed recruitment of mesenchymal cells. The present results indicate that amelogenin has an important role in many tissues of the cranio-facial complex during mouse embryonic development and differentiation, and might be a multifunctional protein.

DOI: <https://doi.org/10.1002/jez.b.21255>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-9207>

Journal Article

Accepted Version

Originally published at:

Gruenbaum-Cohen, Y; Tucker, A S; Haze, A; Shilo, D; Taylor, A L; Shay, B; Sharpe, P T; Mitsiadis, T A; Ornoy, A; Blumenfeld, A; Deutsch, D (2008). Amelogenin in cranio-facial development: the tooth as a model to study the role of amelogenin during embryogenesis. *Journal of Experimental Zoology. Part B: Molecular and Developmental Evolution*, 312B(5):445-457.

DOI: <https://doi.org/10.1002/jez.b.21255>

Amelogenin in Craniofacial Development: The tooth as a model to study the role of Amelogenin during embryogenesis

Yael Gruenbaum-Cohen¹; Abigail S. Tucker²; Amir Haze¹; Dekel Shilo¹; Angela L. Taylor¹; Boaz Shay¹; Paul T. Sharpe²; Thimios A. Mitsiadis³; Asher Ornoy⁴; Anat Blumenfeld¹; and Dan Deutsch¹

¹ *Dental Research Laboratory, Institute of Dental Sciences, Hebrew University, Hadassah, Faculty of Dental Medicine, Jerusalem, Israel.* ² *Department of Craniofacial Development, Dental Institute, King's College, Guy's Campus, London, England.* ³ *Institute for Oral Biology, Department of Orofacial & Structural Biology, University of Zurich, Faculty of Medicine, Zurich, Switzerland* ⁴ *Laboratory of Teratology, Department of Anatomy and Cell Biology, Hebrew University – Hadassah Medical School, Jerusalem, Israel.*

Running title: Amelogenin in embryonic craniofacial and tooth development

Key words: Amelogenin, spatio-temporal expression, mouse embryonic craniofacial development, mesenchymal cell recruitment

Corresponding Author:

Prof Dan. Deutsch
Head, Dental Research Laboratory
Institute of Dental Sciences
Hebrew University, Hadassah
Faculty of Dental Medicine, Jerusalem, Israel.
Tel: 972-2-6758565
Fax: 972-2-6757307
Email: dddan@cc.huji.ac.il

List of abbreviations:

DMEM - Dulbecco's modified Eagle's medium

LRAP - Leucin-rich amelogenin peptide

PBS - Phosphate buffered saline

PDL - Periodontal ligament

PFA - Para-Formaldehyde

rHAM⁺ - Recombinant human amelogenin protein

RT-PCR - Reverse transcription followed by polymerase chain reaction

Name	Email
Gruenbaum-Cohen Yael	yael.gru@mail.huji.ac.il
Tucker Abigail	abigail.tucker@kcl.ac.uk
Haze Amir	amir.haze@mail.huji.ac.il
Shilo Dekel	dekel.shilo@mail.huji.ac.il
Taylor Angela	angela.taylor@mail.huji.ac.il
Shay Boaz	boaz@endo.co.il
Sharpe Paul	paul.sharpe@kcl.ac.uk
Mitsiadis Tim	mitsiadis@zzmk.unizh.ch
Ornoy Asher	ornoy@cc.huji.ac.il
Blumenfeld Anat	anatbl@savion.huji.ac.il
Deutsch Dan	dddan@cc.huji.ac.il

Abstract

The amelogenins comprise 90% of the developing extracellular enamel matrix proteins and play a major role in the biomineralization and structural organization of enamel. Amelogenins were also detected, in smaller amounts, in postnatal calcifying mesenchymal tissues, and in several non-mineralizing tissues including brain. Low molecular mass amelogenin isoforms were suggested to have signaling activity; to produce ectopically chondrogenic and osteogenic-like tissue and to affect mouse tooth germ differentiation *in vitro*. Recently, some amelogenin isoforms were found to bind to the cell surface receptors; LAMP-1, LAMP-2 and CD63, and subsequently localize to the perinuclear region of the cell. The recombinant amelogenin protein (rHAM⁺) alone brought about regeneration of the tooth supporting tissues: cementum, periodontal ligament and alveolar bone, in the dog model, through recruitment of progenitor cells and mesenchymal stem cells.

We show that amelogenin is expressed in various tissues of the developing mouse embryonic craniofacial complex such as brain, eye, ganglia, peripheral nerve trunks, cartilage and bone, and is already expressed at E10.5 in the brain and eye, long before the initiation of tooth formation. Amelogenin protein expression was detected in the tooth germ (dental lamina) already at E13.5, much earlier than previously reported (E19). Application of amelogenin (rHAM⁺) beads together with DiI, on E13.5 and E14.5 embryonic mandibular mesenchyme and on embryonic tooth germ, revealed recruitment of mesenchymal cells. The present results indicate that amelogenin has an important role in many tissues of the cranio-facial complex during mouse embryonic development and differentiation, and might be a multifunctional protein.

Introduction

The amelogenins, which comprise about 90% of the enamel matrix proteins (Termine *et al.*, 1980), play a major role in the biomineralization and structural organization of enamel (Robinson *et al.*, 1988; Fincham *et al.*, 1994). Amelogenins are hydrophobic molecules that self-assemble *in vitro* and *in vivo* into nanospheric structures which regulate the oriented and elongated growth, shape and size of the enamel mineral crystal (Fincham *et al.*, 1994; Du *et al.*, 2005). During enamel development and mineralization, the amelogenins in the extracellular enamel are sequentially and discretely degraded by specific proteases the metalloprotease Enamelysin (MMP20) and the serine protease KLK4 (Simmer and Hu, 2002). The amelogenins are eventually, together with other enamel matrix proteins, replaced by mineral ions calcium and phosphorus, the enamel finally becoming hard, fully mineralized (96%) and mature (Termine *et al.*, 1980; Deutsch *et al.*, 1995; Robinson *et al.*, 1998).

The mouse amelogenin gene is mapped to the X chromosome (Lau *et al.*, 1989; Fincham *et al.*, 1991), while in the human it maps to Xp22.1-p22.3 and Yp11.2 chromosomes (Lau *et al.*, 1989; Salido *et al.*, 1992). The gene contains 9 exons (Li *et al.*, 1998; Baba *et al.*, 2002) which undergo extensive alternative mRNA splicing (Simmer and Fincham, 1995; Veis, 2003; Papagerakis *et al.*, 2005). The most abundant amelogenin isoform in the mouse enamel is M180, which is encoded by exons 1-7, skipping exon 4.

In human, mutations in the X-chromosomal copy of the amelogenin gene *AMELX* have been associated with the hereditary disease Amelogenesis Imperfecta (Hart *et al.*, 2000). Defective enamel formation has also been demonstrated by knock-down of amelogenin expression using antisense oligonucleotides (Diekwisch *et al.*, 1993), ribozymes (Lyngstadaas *et al.*, 1995) and in amelogenin knock-out and transgenic mice, which resulted in enamel characteristic of hypoplastic amelogenesis imperfecta, with reduced enamel thickness (Gibson *et al.*, 2001).

For decades amelogenin was thought to be exclusively an enamel (epithelial origin) protein. However, in more recent years different isoforms of amelogenin have also been found in the dentin matrix (Hammarstrom *et al.*, 1997; Nebgen *et al.*, 1999) and the odontoblasts (Oida *et al.*, 2002; Papagerakis *et al.*, 2003), during cementogenesis in remnants of Hertwig's root sheath and in periodontal ligament (PDL) cells (Fong and Hammarstrom, 2000; Janones *et al.*, 2005). Very recently, we have described amelogenin expression in long bone cells; osteocytes, osteoblasts and osteoclasts, and some of the bone marrow cells. Amelogenin is also expressed in chondrocytes of the articular cartilage and differentially in cell layers of the epiphyseal growth plate. We have identified amelogenin expression in long bone marrow cells, some of which are mesenchymal stem cells, and in cells surrounding blood vessels (Haze *et al.*, 2007). Amelogenin expression was also identified in cells of non-mineralizing tissues such as the brain, specifically in the glial cells, in salivary glands and in some of the hematopoietic cells such as megakaryocytes and macrophage (Deutsch *et al.*, 2006; Haze *et al.*, 2007). The relatively large number of amelogenin alternatively spliced mRNA translated polypeptides and the fact that amelogenin is expressed in different tissues (calcifying and soft tissues) and of different embryonic origin, possibly reflect different functions of amelogenin.

Low molecular mass amelogenin isoforms were suggested to be signal molecules; were shown to produce ectopically chondrogenic and osteogenic-like tissue and to have different signaling effects on ameloblasts and odontoblasts

differentiation in developing tooth culture model, and when implanted in the tooth pulp (Nebgen *et al.*, 1999; Veis, 2003; Lacerda-Pinheiro *et al.*, 2006a; Lacerda-Pinheiro *et al.*, 2006b;

Zeichner-David *et al.*, 2006; Jegat *et al.*, 2007). Amelogenin (M180), the amelogenin isoform LRAP (leucin-rich amelogenin peptide), and some of the amelogenin degradation products, were found to bind to the cell surface receptors; LAMP-1, LAMP-2 and CD63, which are ubiquitously expressed lysosomal integral membrane proteins that are also localized to the plasma membrane. Shapiro *et al.* found that exogenously added amelogenin moves rapidly into established LAMP-1 positive vesicles that subsequently localize to the perinuclear region of the cell (Shapiro *et al.*, 2007). Zou and colleagues reported the exact regions and sequences that bind amelogenin to these receptors (Zou *et al.*, 2007).

A major discovery that highlights a new role for enamel matrix proteins was the finding that the application of an enamel matrix protein extract to tooth root surfaces in sites of diseased periodontium promotes the regeneration of all the periodontal tissues (Hammarstrom *et al.*, 1997). It was therefore suggested that amelogenin is responsible for this regeneration. Recently, we showed that the recombinant human amelogenin protein (rHAM⁺), produced in the eukaryotic *baculovirus* system (Taylor *et al.*, 2006), causes significant and progressive regeneration of all three tooth supporting tissues; alveolar bone, periodontal ligament (PDL) and cementum, after induction of chronic periodontitis, in the dog. Further immunohistochemistry studies, using markers for mesenchymal stem cells, combined with the above findings, suggested that amelogenin induces, directly or indirectly, recruitment of mesenchymal stem cells and/or progenitor cells, during the regeneration of the tooth supporting tissues (Deutsch *et al.*, 2006).

Large amount of information is available in the literature on genes and their corresponding proteins, associated with embryonic tooth development, morphogenesis and differentiation, such as signaling molecules, growth factors, homeoboxes etc. (Tucker and Sharpe, 1999; Jernvall and Thesleff, 2000; Tucker and Sharpe, 2004; Hu *et al.*, 2006; Mitsiadis and Smith, 2006). The same is true for all other craniofacial organs. However, almost no data is available on amelogenin expression and function in the early stages of embryonic craniofacial development.

In this study we focused on the spatio-temporal expression of amelogenin in different tissues of the developing embryonic mouse craniofacial complex, such as the tooth germ, brain, eye, ganglia, peripheral nerve trunks, cartilage and bone. Our results indicate that amelogenin is expressed in many tissues of the cranio-facial complex during mouse embryonic development and differentiation, pointing to the possibility that it might be a multifunctional protein.

Results

Amelogenin mRNA expression in the craniofacial complex during mouse embryonic days E10.5–E17.5.

The expression of amelogenin mRNA, in the craniofacial complex at E10.5 up to E17.5, was analyzed by RT-PCR, followed by cDNA sequencing (Fig. 1A). The

most abundant amelogenin isoform in the extracellular enamel matrix, M180 (exons 1-7 lacking exon 4, Figure 1B), was detected along the different stages of mouse embryonic cranio-facial development. Other amelogenin isoforms might also be present. We are currently looking for such isoforms.

Spatio-Temporal expression of amelogenin in the cranio-facial complex during E10.5-E18.5 mouse embryonic development (Figure 2)

Amelogenin expression (red – brown staining) was detected in different tissues of the mouse embryonic craniofacial complex, at different stages of development. No staining was observed in the corresponding control (PBS) sections (not shown).

- **Amelogenin expression in the developing eye (Figure 2a)**

At E10.5 positive staining for amelogenin was detected at the outer peripheral area of the inner part of the optic cup (OC), which gives rise to the photoreceptors. At E11.5 staining in the area of the photoreceptors (Pr) facing the future pigment epithelium region, was more intense. At E12.5, faint staining was also detected in fibers at the inner side of the optic nerve, with the precursors of the photoreceptors (Pr) being more intensely stained. Cells at the periphery of the lens stained positively, as well as the lens fibers. In the epithelium that will develop into the cornea few cells were positively stained (Cr). At E13.5, the fibers, connective tissue and choroidal blood vessels (Ch) were positively stained, while still few cells in the cornea (Cr) were stained. At E14.5 lens fibers (LF) were positively stained, and faint staining was detected in most of the cornea (Cr) cells, as well as in the sclera (Sc). Staining was also observed in the vitreous (Vi) but not in the retina (Re), as the photoreceptors loose their staining. At E15.5 the lining epithelium at the anterior part of the lens, as well as the retina (Re), did not stain, while the choroidal blood vessels stained positively (Ch). At E16.5 mainly lens fibers (LF) and the entire choroid (Ch) was positively stained. In the ganglion layer (GC) of the retina (Re), cell bodies (cytoplasm) and fibers were stained, but at that stage the bipolar cell layer, the photoreceptors and the pigment epithelium did not stain with amelogenin antibodies. At E18.5 the lens (LF) was completely stained. The retinal vessels and the sub-epithelial areas (EI) over the eyelids were also stained

- **Amelogenin expression in the developing brain (Figure 2a)**

At E10.5 positive staining for amelogenin was detected in the cranial part of the neural tube at the external limiting membrane (ELM), where glial cells were stained. When fibers were detected – they apparently also stained for amelogenin. Most of the staining in the nerve fibers was probably associated with the glial cells, however, it is not clear if some axons or dendrites were also stained. At E11.5 amelogenin expression was detected in the anterior (ventral) regions of the midbrain (MB), mainly in fiber-like structures and glial cells. Staining was also observed in the tissue that will eventually develop into cartilage at the base of the skull. At E12.5 positive, but weak, amelogenin staining was detected in the medial part (that is rich in fibers) of the telencephalon (Tc), while no staining was detected in the cortical plate (CP), which, at that stage comprised mainly of neuroblasts. In general, amelogenin staining was observed in both brain hemispheres in fiber-like structures. In most cases, the glial cells stained positively, but other cell types (neurons) might also be involved. At E13.5, fibers (white material under the cortical plate) stained positively while no staining was detected in the cortical neurons. At E14.5 dispersed positive

staining of glial cells throughout the brain especially in the midbrain (MB) and pons (P), and not only in fiber-like structures, was detected. At E15.5, staining of nerve fibers in the mid-brain (MB) was less prominent, but faint staining in the cerebral cortex (CP) was now demonstrated. At E16.5 and E18.5, staining was detected throughout the brain except for a thin layer of cortical neurons and around the lateral ventricle that was negative (LV). Stronger staining was detected at regions rich in fibers or where neurons were not dense; this staining was detected in glial cells. However it is unclear if neurons, axons and dendrites were also stained.

- **Amelogenin expression in the developing peripheral nerve tracts and fibers (Figure 2a)**

At E10.5 almost no nerve fibers were detected. At E11.5 - E16.5 amelogenin expression was detected in the developing peripheral nerve (NF), most probably in the glial cells. It is unclear if axons and/or dendrites were also stained.

- **Amelogenin expression in the developing ganglia and cervical spinal cord (Figure 2b)**

At E10.5 the neural tube was not stained for amelogenin. At E11.5 amelogenin expression was not detected in the trigeminal ganglion, or in the spinal cord. At E12.5 amelogenin staining was observed in fiber-like structures in the ventral part of the spinal cord. In sites of the spinal cord where vertebrae were more organized – less amelogenin staining was detected. At E13.5 positive staining was detected in dorsal spinal cord ganglia, however, it is not yet clear which type of cells were stained. At E14.5 the entire spinal cord stained positively for amelogenin; the staining was further intensified at E15.5. From E14.5 and thereafter up to E18.5 the trigeminal ganglion and ganglia at the vicinity of the tooth germ stained positively.

- **Amelogenin expression in the developing tooth germ (Figure 2b)**

At E13.5 cells in the dental lamina (DL) were positively stained. At E14.5, in the tooth germ (TG), specifically in the region of the stellate reticulum (SR) faint positive staining was also detected. At E15.5 staining was still detected in the dental lamina (DL), and was also detected in the inner enamel epithelium (IEE). At E16.5, staining was observed in the inner enamel epithelium (IEE) and stratum intermedium (SI). Faint staining was detected in the stellate reticulum (SR) and almost no staining – in the outer enamel epithelium (OEE). The oral epithelium was also stained (not shown) while the cervical loop (CL) was faintly stained. Amelogenin staining was also detected in developing alveolar bone trabeculae (Av). At E18.5 the dental papilla (DP), odontoblasts (Od) and pre-dentin (PD) were slightly stained, the dentin (D) did not seem to be stained, followed by very strong purple brown staining of the developing extracellular enamel matrix (EM). The ameloblasts (Ab) were stained, but not at the outmost region of the ameloblast's cell nucleus. The stratum intermedium (SI) and stellate reticulum (SR) surrounding the ameloblasts were only slightly stained. These layers are covered by the outer enamel epithelium, which was also positively stained.

- **Amelogenin expression in the developing cartilage (Figure 2b)**

At E11.5, before cartilage was detected, amelogenin staining was observed in the tissue that will eventually develop into cartilage (Pc- prechondrocytes) at the base of the skull. At E12.5 some staining was detected in the developing cartilage, mainly in surrounding blood vessels but also in some chondrocytes. At E13.5 the cartilage of

the vertebrae alongside the cervical spinal cord stained positively. The chondrocytes that were not fully differentiated did not stain, while differentiated chondrocytes (DC) that underwent hypertrophy stained positively for amelogenin. At E14.5, prehypertrophic and hypertrophic chondrocytes (WDC) and the cartilage beneath the perichondrium stained positively. This was also observed at E15.5 and E16.5, as hypertrophic cartilage (HC) and perichondrium, as well as blood vessels in various cranio-facial regions stained positively for amelogenin. At E18.5 both chondrocytes and blood vessels in the hypertrophic cartilage stained positively.

- **Amelogenin expression in the developing bone (Figure 2b)**

Bone in the craniofacial region was first detected at E13.5. At that developmental stage periosteal osteoblasts, at the beginning of bone organization, stained positively. At E14.5, most cell types and not just osteoblasts in the cranial bones (mainly membranous bone which does not develop from cartilage), were positively stained. The mandibular alveolar bone, which is composed of periosteal bone, stained positively at E14.5 and E15.5. However, only faint staining was detected in the endochondral mandibular condyle. At E16.5, both endochondral and membranous bones in the mandible, maxilla, and their surrounding periosteum, stained for amelogenin. This positive staining was also observed at E18.5.

- **Amelogenin expression in additional developing tissues (not shown)**

From E10.5 through E18.5 the mesenchyme and connective tissue was positively stained for amelogenin. On E11.5 amelogenin expression was detected in loosely packed mesenchymal cells at the base of the skull. Amelogenin staining at E11.5 was also detected at the region of both, yet vertical, palatine shelves. The palate continued to be positive at least until E15.5. The skin and the connective tissue just beneath the skin epithelium (future dermis) did not stain at E11.5-E16.5. Only at E18.5 the dermis stained positively for amelogenin, while the epithelium still did not stain. At E13.5 the connective tissue surrounding the brain (brain membranes) stained positively. At E15.5 amelogenin staining was detected in the salivary glands, which apparently disappeared at E18.5.

Recruitment of mesenchymal cells by amelogenin in the developing mandible

Agarose beads containing the recombinant human amelogenin (rHAM⁺, long black arrow) (Taylor et al. 2006), were placed along different regions of the mandibular mesenchyme of E13.5 mouse embryos. The experimental beads were on one side of the mandible, while the control beads (long white arrow) were on the contra-lateral side. The ex-vivo mandible was placed in culture for one day and then coronal sections were made. Mesenchymal cells apparently moved towards the rHAM⁺ beads and surround the beads (short arrows), while no such cell recruitment could be seen around the control PBS agarose bead (Figure 3).

Recruitment of mesenchymal cells by amelogenin in the developing incisor tooth germ

Agarose beads containing rHAM⁺ or PBS (control) were placed on the mesenchymal region of the incisor tooth germ of 250µm frontal sections of E14.5 mandibles. Changes in DiI distribution between 0 and 3 days in culture showed movement (recruitment) of mesenchymal cells towards the rHAM⁺ bead (Figure 4 A-

D), which eventually partially covered the bead, while no such movement was observed towards the control PBS bead (Figure 4 E-H).

Discussion

In the present study we focused on the spatio-temporal expression of amelogenin in different tissues of the developing embryonic mouse craniofacial complex. Our results indicate possible signaling and structural roles for amelogenin during early stages of embryonic craniofacial development, in addition to its known function during enamel biomineralization. The results clearly show that the expression of amelogenin in different tissues is dynamic and depends on the embryonic developmental stage. The recruitment of mesenchymal cells in the tooth germ and mandible, at early stages of embryonic development, points to the functional significance of amelogenin in these tissues.

Many studies in the field of molecular biology and biochemistry, have described the function of amelogenin in structural organization and biomineralization of enamel; in controlling the size, shape and direction of formation of the enamel mineral crystallites (Fincham *et al.*, 1994; Du *et al.*, 2005). In the past few years, cell signaling functions have been attributed to amelogenin low-mass isoforms such as LRAP (A-4/M59) (Nebgen *et al.*, 1999; Veis, 2003; Lacerda-Pinheiro *et al.*, 2006a; Lacerda-Pinheiro *et al.*, 2006b; Zeichner-David *et al.*, 2006; Jegat *et al.*, 2007,). The cell surface receptors for amelogenin (M180 and LRAP), were identified, and the exact binding regions of amelogenin to its receptors was deciphered (Shapiro *et al.*, 2007; Zou *et al.*, 2007). We have recently shown that recombinant human amelogenin (equivalent to M180) brought about regeneration of the tooth supporting mesenchymal tissues: cementum, periodontal ligament and alveolar bone in the dog model. This regeneration process involved recruitment of mesenchymal stem cells, also indicating signaling role(s) for amelogenin (Haze. *et al.* in submission). All these studies were performed on postnatal tissues. Very few detailed studies were carried out on amelogenin expression in the cranio-facial complex during prenatal development, and these studies focused mainly on the late stages of prenatal development when ameloblasts and odontoblasts had already differentiated, and begun to produce developing enamel and the underlying dentin (Zeichner-David *et al.*, 1997; Lacerda-Pinheiro *et al.*, 2006b). This is in contrast to the vast information in the literature on other genes, their corresponding proteins and the pathways associated with embryonic cranio-facial and specifically with tooth development, morphogenesis and differentiation (Tucker and Sharpe, 1999; Jernvall and Thesleff, 2000; Tucker and Sharpe, 2004; Mitsiadis and Smith, 2006).

In the present study we showed that amelogenin mRNA (Figure 1) and protein (Figure 2) are expressed in the craniofacial complex from early stages of development (E10.5). Amelogenin protein is expressed in some tissues of the cranio-facial complex long before the initiation of tooth formation. The amelogenin protein was mainly identified in glial cells, in neural-crest derived cells and possibly (but it is still not clear yet) in neurons, as it was detected in the brain, the retina of the eye, peripheral ganglia and the peripheral nerve trunks. In the craniofacial complex, neural crest cells also give rise to non-neuronal ecto-mesenchymal tissues such as bone, cartilage and mesenchymal regions of the teeth (Le Douarin *et al.*, 2007) that were all positive for

amelogenin. Interestingly, the strongest staining for amelogenin was detected in the ameloblasts, extracellular enamel matrix, and the eye lens, that are not thought to be neural crest derived. Other epithelial tissues were not intensely stained (cornea), or staining was detected at later stages of development (skin, eyelids).

The expression of amelogenin was studied during mouse embryonic tooth germ development, from early stages of development, when the information on the spatio-temporal expression of amelogenin is rather scarce, to E18.5, when amelogenin expression in the tooth germ (near birth) and postnatally is well documented. Amelogenin protein expression was seen already at E13.5 in the dental lamina, and continued through embryonic tooth development to E18.5. From E13.5 up to E16.5 (E17.5 was not analyzed), no extracellular enamel or dentin are yet formed, and no biomineralization of enamel or dentin takes place. Amelogenin, therefore, has different function(s) at these stages than that of regulating the size, shape and direction of mineral crystal growth. Late in development and close to birth (E18.5), amelogenin expression was mainly seen in the mineralizing extracellular enamel matrix and in the secreting ameloblasts, and also in the stratum intermedium, predentin and dentin, and some expression in the dental papilla. The latter expression pattern, observed by us at E18.5, has been extensively described, mainly in postnatal mice.

A hint on amelogenin function in the early stages of tooth and mandible development emerges from the application of amelogenin beads on E13.5 mouse embryonic mandibular mesenchyme, which brought about recruitment and cell movement towards the beads (Figure 3). This observation was strengthened by the application of amelogenin beads, in combination with DiI application, on E13.5 and E14.5 embryonic incisor and first molar (not shown) tooth germs mesenchymal tissue, respectively. The DiI, which binds to cell membranes, revealed movement of mesenchymal cells towards the amelogenin beads, partially covering the beads after 2 and 3 days (Figure 4). The amelogenin beads contained the recombinant human amelogenin protein rHAM⁺, which is the human amelogenin isoform corresponding to the mouse isoform M180 (which contains exons 1-7, lacking exon 4). No such recruitment of mesenchymal cells was detected towards the control PBS bead. Since amelogenin is endogenously expressed in these mesenchymal and tooth germ tissues at the days rHAM⁺ beads were applied (Figure 2), these experiments represent over-expression and not ectopic expression. The observed cell recruitment suggests a signaling function for amelogenin. This is in line with the accumulating data on the signaling function of amelogenin, including our recent data (Haze *et al.* in submission). Other studies in which low molecular mass amelogenin isoforms produced ectopically chondrogenic and osteogenic-like tissue and caused ameloblasts and odontoblasts differentiation suggested prenatal and postnatal signaling effects for the different amelogenin isoforms (Nebgen *et al.*, 1999; Veis, 2003; Lacerda-Pinheiro *et al.*, 2006a; Lacerda-Pinheiro *et al.*, 2006b; Jegat *et al.*, 2007,) (also see introduction on possible signaling activity of amelogenin).

As was previously described, amelogenin, which is a structural protein during enamel bio-mineralization, regulates the shape, size and direction of mineral crystal growth. The patterns of amelogenin expression in lens fibers, in brain fibers and in nerve trunk fibers suggest a possible role for amelogenin in elongating structures within some developing cells. It is tempting to speculate that the model of elongated amelogenin nanospheres (Du *et al.*, 2005) might be somehow relevant to its role in

developing fibers, but other mechanisms are also feasible. In the eye, amelogenin is mainly expressed in the posterior lens epithelium cells which elongate up to several hundred times during the process of differentiation into fiber cells. In the nervous tissues; brain, optic nerve and nerve trunks, amelogenin expression was mostly localized to fiber like structures. Glial and mesenchymal cells are known to surround nerve fibers, whether they are axons or dendrites. Several lines of evidence indicate that amelogenin is mainly expressed by the glial cells; (i) virtually no staining for amelogenin was detected in the cortex, which is mainly composed of neuroblasts, while the sub-cortical regions, where many more glial cells exist, was positively stained for amelogenin. (ii) Amelogenin was detected in postnatal glial cells surrounding brain neurons but not in the neurons themselves (Deutsch et al., 2006). A major role of glial cells during development is to support and direct the growth and elongation of neurons.

In 2001, the phenotype of the amelogenin knock out (null) mouse was published. The only phenotype described at that time was of abnormal enamel formation; the teeth of the amelogenin null mouse expressed a hypoplastic enamel phenotype with reduced enamel thickness (Gibson et al., 2001). As often happens, additional, different phenotypes of the amelogenin null mouse were later described. A progressive deterioration of cementum (a mineralized tissue covering the tooth root surface) was observed in the amelogenin null mouse. The defects in cementum were characterized by increased presence of osteoclasts, and were also associated with an increased expression of receptor activator of nuclear factor- κ B ligand (RANKL) near the cementum, suggesting that amelogenin may play a role in osteoclastogenesis through the RANKL/RANK mediated pathway (Hatakeyama et al., 2003). In 2006, an additional phenotypic defect was published: the weight of the null mouse was significantly reduced compared to the wild type (Li et al., 2006). No reports have been made on phenotypes in other cranio-facial tissues and body organs. This is not surprising, since only at 2006 amelogenin expression in other mesenchymal mineralizing tissues, such as alveolar bone, long bone and cartilage, and in cranio-facial soft tissues such as brain and salivary gland were published (Deutsch *et al.*, 2006; Haze *et al.*, 2007). Our recent findings of amelogenin expression in active alveolar bone regions (Haze *et al.* in submission), in epiphyseal growth plate of long bone, its expression in osteoblasts, osteoclasts and osteocytes, as well as the periosteum suggest that amelogenin is active in bone formation and remodeling (Haze et al., 2007). Indeed, as was described above, we found that the recombinant amelogenin brought about regeneration of the tooth supporting tissues via recruitment of mesenchymal stem cells (Haze *et al.* in submission). In the present study it is evident that the expression of amelogenin in different cranio-facial tissues is dynamic and depends on embryonic stage. Our results suggest that additional phenotypes might be revealed when cranio-facial and body tissues in which amelogenin was found to be expressed in the wild type, will be studied in the null mouse. However, it is possible that different compensation pathways lead to normal phenotype in other tissues of the knockout mice.

The present study suggests that amelogenin could have structural and signaling roles in the development of various tissues of the cranio-facial complex

including the developing tooth germ, and also in other body organs. The results of the present study open new horizons as to the function(s) of amelogenin in different tissues during embryonic cranio-facial development. Naturally, there are numerous questions that can be asked and many studies that can be conducted to reveal the molecular mechanisms and pathways with which amelogenin is associated.

Materials and Methods

Animals

Embryos from CD-1 mice aged E10.5-E18.5, were used in the present study. Embryos from 6 pregnant mice were used for each age. All experiments were approved by the Animal Care Ethical Committee of the Faculty of Medicine, The Hebrew University of Jerusalem.

Preparation of Embryonic tissues

Pregnant mice were sacrificed, the embryos were immediately collected, and the heads were removed for further analyses. For histology and immunohistochemistry, the heads were immediately fixed in 4% Para-Formaldehyde (PFA) over-night at 4°C. The tissues were then washed several times in PBS, and dehydrated in increasing ethanol concentrations of 30%, 50%, 70%, 80%, 85%, 90%, 95%, and 100%. The tissues were then immersed in Histoclear / Xylene, embedded in paraffin and frontally sectioned (5µm) from the nose in an anterior-posterior direction. For mRNA and protein analysis heads were immediately immersed in TRI-REAGENT (MRC, Cincinnati, OH).

RNA isolation and RT-PCR

Total RNA was extracted by homogenizing the craniofacial complexes of E10.5-E17.5 in TRI-REAGENT (MRC, Cincinnati, OH). RNA isolation was performed using the TRI-REAGENT standard protocol. All total RNA extracts were subjected to DNase treatment (DNA free, Ambion, Austin, TX) to eliminate any possible DNA contamination. Total RNA concentration was determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Total RNA was subjected to reverse transcription according to the manufacturer's protocol (Superscript RNase H- Reverse Transcriptase kit, Invitrogen, Carlsbad, CA). RT and PCR amplification were performed using primers designed according to the mouse amelogenin sequence (Gibson et al, 2003), Forward, DD391: 5'-AGA AAC TCA CTG AGC ATA CAC-3', and reverse, DD390, 5'-GAT GGA GGG ATG TTT GGC TG-3'. PCR products were extracted from 2% agarose gels using Qiaquick gel extraction kit (Qiagen, Valencia, CA) and sequenced at the Center for Genomic Technologies, Hebrew University (Jerusalem, Israel).

Indirect Immunohistochemistry:

Slides were deparaffinized, hydrated, rinsed in PBS and endogenous peroxidase activity was blocked by 3% H₂O₂ (diluted in methanol) for 10 min. Slides were blocked in non-immune goat serum for 20 min (Histostain-SP kit, Zymed laboratories Inc., San Francisco, USA), followed by over-night incubation of the primary antibody (diluted in PBS) at 4°C in a humidified chamber. The first antibodies used were: (a) 270-Polyclonal rabbit antibody, raised against amelogenin N-terminus (MPLPPHPG)

(identical in mouse, human etc.) and diluted in PBS to 1/500-1/1000. (b) 859 polyclonal rabbit antibody raised against rat amelogenin. The specificity of the antibodies was previously determined (Haze *et al.* in submission), by subjecting the antibodies to sections obtained from the amelogenin knockout mouse (Gibson et al., 2001) mandible. No staining for amelogenin was obtained in the mandible, including, amongst others, the ameloblasts and enamel. On the other hand, using the same conditions, some of the corresponding wild type tissues, including the ameloblasts and enamel showed strong staining for amelogenin.

After rinsing, slides were treated according to the Histostain-SP kit protocol (Zymed laboratories inc., San Francisco, USA). Negative controls included PBS in place of the first antibody. For better viewing of the histology of the tissue, the slides were stained with hematoxylin (Pioneer Research Chemicals, USA, blue staining). All slides were examined by Axioskop (Zeiss, Göttingen, Germany). The pictures were taken using Coolpix 990 digital camera (Nikon, Tokyo, Japan), and ProgRes C10 (Jenoptik, Jena, Germany).

Preparation and culturing of mouse embryonic mandibles

Freshly harvested (13.5 day) embryo heads were placed in Dulbecco's modified Eagle's medium (DMEM) (with L-glutamatmine), containing 20 units/ml penicillin/streptomycin (Beit Ha'emek, Israel;Sigma). The mandibles were dissected from the cranio-facial complex by using watchmaker's forceps (FST, Vancouver, Canada) and 27-gauge sterile needles (Sherwood Medical Industries, Athy, Ireland). The dissected mandibles were then placed on a 0.1- μ m Millipore filter (Millipore, USA) coated with Matrigel (BD Biosciences, USA), and then covered with Matrigel. The filter paper with the mandible was then placed on a 35mm triangle stainless steel metal grid, with 0.25mm diameter mesh wire (Goodfellows), placed in Falcon 60mm Center-well Organ Culture dishes (Becton Dickinson). The center well was filled with DMEM (with L-glutamatmine) and 20 u/ml penicillin/streptomycin, up to the mesh surface, and the narrow well, surrounding the center well, was filled with double distilled sterile water. The cultures were grown in a standard incubator at 37°C with an atmosphere of 5% CO₂. After incubation in culture for one day, explants were washed in ice-cold methanol for 2 min and then fixed in 4% paraformaldehyde for 2h at room temperature. The explants were then embedded in paraffin, sectioned, and counterstained with eosin for histology.

Bead preparation and placement on mouse embryonic mandible explant cultures

Affi-gel agarose beads (Biorad) (75-100 μ m) were separated by size under stereomicroscope, washed thoroughly in PBS, air dried, and suspended in rHAM⁺ (Taylor et al. 2006) (1 μ g/ μ l) dissolved in 0.05M acetic acid solution, at 37°C for 30 min. Prior to use, beads were washed in PBS (neutralizing the acid), and the beads were then placed on E13.5 mandibular explant, in the incisor region, the molar region, and on the mandible diastema region (experimental beads). Control beads were prepared in a similar manner by using only PBS, and were placed on the contralateral side of the mandible in similar regions as the experimental beads. Mouse embryonic mandible explant cultures containing Affi-gel beads were grown for one day, as described below

Preparation of 250 μ m thick frontal sections of mouse embryonic mandibles for DiI studies

E13.5 and E14.5 mouse embryonic mandibles were frontally dissected into 250µm thick sections, using McIlwain Tissue Chopper (Science Products GmbH, Hofheim, Germany) as described in Matalova *et al.*, 2005. Briefly, sections containing first molars, or incisors, were selected under the microscope in medium. Affi-gel beads (control and experimental) were placed on the tooth germ mesenchymal region, and DiI (Molecular probes, USA) was injected into the mesenchymal cells in the vicinity of the beads using a mouth pipette. Slices were placed on a 0.4-µm Falcon™ cell culture inserts (Falcon, USA). The sliced tissue was then covered with Matrigel (BD Biosciences, USA), and cultured as was described above for the mandibular explant for up to 3 days. The cultures were photographed every 24 hours using a Leica dissecting microscope under either bright field, dark field or both (for superimposition) to monitor the DiI at 0, 1 and 2 days. Cultures were fixed at day 2 and embedded in wax for sectioning. After sectioning the localization of DiI was photographed using a Zeiss Fluorescence compound microscope. Sections were then stained for histology and re-photographed. The DiI label is fixable but lost after staining for histology.

Acknowledgements:

The authors thank Dr. Carolyn W. Gibson, University of Pennsylvania, Philadelphia, PA, for her generous gift of the 270 and 859 amelogenin antibodies. We are grateful to Dr. Shahar Frenkel, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, for the useful comments on eye development. The authors are grateful for the supports of the COST Action B23 for funding short term missions. This work was supported by Israel Science Foundation (ISF) grant no. 597/02 to DD,

Figure legends:





Fig. 1. (A) Expression of amelogenin cDNA isoform M180 in the mouse embryonic cranio-facial complex at E10.5 through E17.5. (B) Schematic representation of the exon structure of M180.






Fig. 2. Spatio-temporal distribution of amelogenin expression in tissues of E10.5 to E18.5 mouse embryonic cranio-facial complex (Amelogenin expression - brown-red staining, hematoxylin – blue staining). **(A)** In the eye, brain and peripheral nerve trunk at E10.5, E11.5, E12.5, E13.5, E14.5, E15.5, E16.5 and E18.5. **(B)** In the tooth germ, cartilage, bone and ganglion at E12.5, E13.5, E14.5, E15.5, E16.5 and E18.5. Eye: Ch- choroidal blood vessels; Cr- cornea; EI- sub-epithelial region; GC- ganglion layer; LF- lens fibers; OC- optic cup; Pr- photoreceptors; Re- retina; Sc- sclera; Vi- vitreous. Brain: C- cortex; CP- cortical plate; ELM- external limiting membrane; LV- lateral ventricle; MB- midbrain; P- pons; Tc- telencephalon; TCr- temporal cortex TL- temporal lobe. Peripheral nerve trunk: NF- peripheral nerve fibers. Tooth germ: Ab- ameloblasts; Av- alveolar bone trabecules; CL- cervical loop; D- dentin; DL- dental lamina; DP- dental papilla; EM- extracellular enamel matrix; IEE- inner enamel epithelium; Od- odontoblasts; OEE- outer enamel epithelium; PD- pre-dentin; SI- stratum intermedium; SR- stellate reticulum; TG- tooth germ. Cartilage: DC- differentiated chondrocytes; HC – Hypertrophic cartilage; Pc- Pre-chondrocytes; WDC – well developed chondrocytes. Bone: BT – bone trabecules. No amelogenin staining was detected in the corresponding control (PBS) sections (not shown).




Fig. 3. Possible recruitment of mesenchymal cells in the developing mandible by amelogenin (rHAM⁺) beads but not by control PBS beads. (A, B) rHAM⁺ beads (long black arrow) one days after bead application on E13.5 mouse embryonic mandibles. Note the ring of cells surrounding the rHAM⁺ beads (short arrows). (C) PBS bead (long white arrow). No such phenomenon is detected around the control bead.




Fig 4. Movement (recruitment) of DiI – labeled mesenchymal cells in the incisor tooth germ region, towards amelogenin (rHAM⁺) beads but not towards control PBS bead. Frontal slices through the incisor region of E14.5 mandibles cultured for three days after addition of beads. Oral and incisor epithelium are outlined in white. The mesenchyme around the incisor cap stage tooth germs (outlined and marked by *) was labeled with DiI (orange). (A-D) rHAM⁺ bead at day 0 (A), day 1 (B), day 2 (C), day 3 (D). (A-C) Merged light/dark field image of cultured slice showing DiI label

moving towards and around the rHAM⁺ bead. (D) Section showing DiI cells associated with the rHAM⁺ bead. (E-H) Similar slice with a PBS (control) bead at day 0 (A), day 1 (B), day 2 (C), day 3 (D). (E-G) Merged light/dark field image of cultured slice showing DiI label remaining distinct from the PBS bead. (H) Section showing DiI cells not associated with the PBS bead.

References:

- BABA, O., TAKAHASHI, N., TERASHIMA, T., LI, W., DENBESTEN, P.K. and TAKANO, Y. (2002). Expression of alternatively spliced rna transcripts of amelogenin gene exons 8 and 9 and its end products in the rat incisor. *J Histochem Cytochem* 50: 1229-36.
- DEUTSCH, D., CATALANO-SHERMAN, J., DAFNI, L., DAVID, S. and PALMON, A. (1995). Enamel matrix proteins and ameloblast biology. *Connect Tissue Res* 32: 97-107.
- DEUTSCH, D., HAZE-FILDERMAN, A., BLUMENFELD, A., DAFNI, L., LEISER, Y., SHAY, B., GRUENBAUM-COHEN, Y., ROSENFELD, E., FERMON, E., ZIMMERMANN, B. *et al.* (2006). Amelogenin, a major structural protein in mineralizing enamel, is also expressed in soft tissues: Brain and cells of the hematopoietic system. *Eur J Oral Sci* 114 Suppl 1: 183-9; discussion 201-2, 381.
- DIEKWISCH, T., DAVID, S., BRINGAS, P., JR., SANTOS, V. and SLAVKIN, H.C. (1993). Antisense inhibition of amel translation demonstrates supramolecular controls for enamel hap crystal growth during embryonic mouse molar development. *Development* 117: 471-82.
- DU, C., FALINI, G., FERMANI, S., ABBOTT, C. and MORADIAN-OLDAK, J. (2005). Supramolecular assembly of amelogenin nanospheres into birefringent microribbons. *Science* 307: 1450-4.
- FINCHAM, A.G., BESSEM, C.C., LAU, E.C., PAVLOVA, Z., SHULER, C., SLAVKIN, H.C. and SNEAD, M.L. (1991). Human developing enamel proteins exhibit a sex-linked dimorphism. *Calcif Tissue Int* 48: 288-90.
- FINCHAM, A.G., MORADIAN-OLDAK, J., SIMMER, J.P., SARTE, P., LAU, E.C., DIEKWISCH, T. and SLAVKIN, H.C. (1994). Self-assembly of a recombinant amelogenin protein generates supramolecular structures. *J Struct Biol* 112: 103-9.
- FONG, C.D. and HAMMARSTROM, L. (2000). Expression of amelin and amelogenin in epithelial root sheath remnants of fully formed rat molars. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 90: 218-23.
- GIBSON, C.W., YUAN, Z.A., HALL, B., LONGENECKER, G., CHEN, E., THYAGARAJAN, T., SREENATH, T., WRIGHT, J.T., DECKER, S., PIDDINGTON, R. *et al.* (2001). Amelogenin-deficient mice display an amelogenesis imperfecta phenotype. *J Biol Chem* 276: 31871-5.
- HAMMARSTROM, L., HEIJL, L. and GESTRELIUS, S. (1997). Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. *J Clin Periodontol* 24: 669-77.
- HART, P.S., VLASERVICH, A.C., HART, T.C. and WRIGHT, J.T. (2000). Polymorphism (g2035c>t) in the amelogenin gene. *Hum Mutat* 15: 298.
- HATAKEYAMA, J., SREENATH, T., HATAKEYAMA, Y., THYAGARAJAN, T., SHUM, L., GIBSON, C.W., WRIGHT, J.T. and KULKARNI, A.B. (2003). The receptor activator of nuclear factor-kappa b ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice. *J Biol Chem* 278: 35743-8.
- HAZE, A., TAYLOR, A.L., BLUMENFELD, A., ROSENFELD, E., LEISER, Y., DAFNI, L., SHAY, B., GRUENBAUM-COHEN, Y., FERMON, E., HAEGEWALD, S. *et al.* (2007). Amelogenin expression in long bone and cartilage cells and in bone marrow progenitor cells. *Anat Rec (Hoboken)* 290: 455-60.

- HU, B., NADIRI, A., KUCHLER-BOPP, S., PERRIN-SCHMITT, F., PETERS, H. and LESOT, H. (2006). Tissue engineering of tooth crown, root, and periodontium. *Tissue Eng* 12: 2069-75.
- JANONES, D.S., MASSA, L.F. and ARANA-CHAVEZ, V.E. (2005). Immunocytochemical examination of the presence of amelogenin during the root development of rat molars. *Arch Oral Biol* 50: 527-32.
- JEGAT, N., SEPTIER, D., VEIS, A., POLIARD, A. and GOLDBERG, M. (2007). Short-term effects of amelogenin gene splice products a+4 and a-4 implanted in the exposed rat molar pulp. *Head Face Med* 3: 40.
- JERNVALL, J. and THESLEFF, I. (2000). Reiterative signaling and patterning during mammalian tooth morphogenesis. *Mech Dev* 92: 19-29.
- LACERDA-PINHEIRO, S., JEGAT, N., SEPTIER, D., PRIAM, F., BONNEFOIX, M., BITARD, J., KELLERMANN, O., TOMPKINS, K., VEIS, A., GOLDBERG, M. *et al.* (2006a). Early in vivo and in vitro effects of amelogenin gene splice products on pulp cells. *Eur J Oral Sci* 114 Suppl 1: 232-8; discussion 254-6, 381-2.
- LACERDA-PINHEIRO, S., SEPTIER, D., TOMPKINS, K., VEIS, A., GOLDBERG, M. and CHARDIN, H. (2006b). Amelogenin gene splice products a+4 and a-4 implanted in soft tissue determine the reorientation of cd45-positive cells to an osteo-chondrogenic lineage. *J Biomed Mater Res A* 79: 1015-22.
- LAU, E.C., MOHANDAS, T.K., SHAPIRO, L.J., SLAVKIN, H.C. and SNEAD, M.L. (1989). Human and mouse amelogenin gene loci are on the sex chromosomes. *Genomics* 4: 162-8.
- LE DOUARIN, N.M., BRITO, J.M. and CREUZET, S. (2007). Role of the neural crest in face and brain development. *Brain Res Rev* 55: 237-47.
- LI, W., MATHEWS, C., GAO, C. and DENBESTEN, P.K. (1998). Identification of two additional exons at the 3' end of the amelogenin gene. *Arch Oral Biol* 43: 497-504.
- LI, Y., YUAN, Z.A., ARAGON, M.A., KULKARNI, A.B. and GIBSON, C.W. (2006). Comparison of body weight and gene expression in amelogenin null and wild-type mice. *Eur J Oral Sci* 114 Suppl 1: 190-3; discussion 201-2, 381.
- LYNGSTADAAS, S.P., RISNES, S., SPROAT, B.S., THRANE, P.S. and PRYDZ, H.P. (1995). A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. *Embo J* 14: 5224-9.
- MITSIADIS, T.A. and SMITH, M.M. (2006). How do genes make teeth to order through development? *J Exp Zool B Mol Dev Evol* 306: 177-82.
- NEBGEN, D.R., INOUE, H., SABSAY, B., WEI, K., HO, C.S. and VEIS, A. (1999). Identification of the chondrogenic-inducing activity from bovine dentin (bcia) as a low-molecular-mass amelogenin polypeptide. *J Dent Res* 78: 1484-94.
- OIDA, S., NAGANO, T., YAMAKOSHI, Y., ANDO, H., YAMADA, M. and FUKAE, M. (2002). Amelogenin gene expression in porcine odontoblasts. *J Dent Res* 81: 103-8.
- PAPAGERAKIS, P., IBARRA, J.M., INOZENTSEVA, N., DENBESTEN, P. and MACDOUGALL, M. (2005). Mouse amelogenin exons 8 and 9: Sequence analysis and protein distribution. *J Dent Res* 84: 613-7.
- PAPAGERAKIS, P., MACDOUGALL, M., HOTTON, D., BAILLEUL-FORESTIER, I., OBOEUF, M. and BERDAL, A. (2003). Expression of amelogenin in odontoblasts. *Bone* 32: 228-40.

- ROBINSON, C., BROOKES, S.J., SHORE, R.C. and KIRKHAM, J. (1998). The developing enamel matrix: Nature and function. *Eur J Oral Sci* 106 Suppl 1: 282-91.
- ROBINSON, C., KIRKHAM, J., WEATHERELL, J.A., RICHARDS, A., JOSEPHSEN, K. and FEJERSKOV, O. (1988). Mineral and protein concentrations in enamel of the developing permanent porcine dentition. *Caries Res* 22: 321-6.
- SALIDO, E.C., YEN, P.H., KOPRIVNIKAR, K., YU, L.C. and SHAPIRO, L.J. (1992). The human enamel protein gene amelogenin is expressed from both the x and the y chromosomes. *Am J Hum Genet* 50: 303-16.
- SHAPIRO, J.L., WEN, X., OKAMOTO, C.T., WANG, H.J., LYGSTADAAS, S.P., GOLDBERG, M., SNEAD, M.L. and PAINE, M.L. (2007). Cellular uptake of amelogenin, and its localization to cd63, and lamp1-positive vesicles. *Cell Mol Life Sci* 64: 244-56.
- SIMMER, J.P. and FINCHAM, A.G. (1995). Molecular mechanisms of dental enamel formation. *Crit Rev Oral Biol Med* 6: 84-108.
- SIMMER, J.P. and HU, J.C. (2002). Expression, structure, and function of enamel proteinases. *Connect Tissue Res* 43: 441-9.
- TAYLOR, A.L., HAZE-FILDERMAN, A., BLUMENFELD, A., SHAY, B., DAFNI, L., ROSENFELD, E., LEISER, Y., FERMON, E., GRUENBAUM-COHEN, Y. and DEUTSCH, D. (2006). High yield of biologically active recombinant human amelogenin using the baculovirus expression system. *Protein Expr Purif* 45: 43-53.
- TERMINE, J.D., BELCOURT, A.B., CHRISTNER, P.J., CONN, K.M. and NYLEN, M.U. (1980). Properties of dissociatively extracted fetal tooth matrix proteins. I. Principal molecular species in developing bovine enamel. *J Biol Chem* 255: 9760-8.
- TUCKER, A. and SHARPE, P. (2004). The cutting-edge of mammalian development; how the embryo makes teeth. *Nat Rev Genet* 5: 499-508.
- TUCKER, A.S. and SHARPE, P.T. (1999). Molecular genetics of tooth morphogenesis and patterning: The right shape in the right place. *J Dent Res* 78: 826-34.
- VEIS, A. (2003). Amelogenin gene splice products: Potential signaling molecules. *Cell Mol Life Sci* 60: 38-55.
- VEIS A. (2005) A window on biomineralization *Science* 307:1419-1420
- ZEICHNER-DAVID, M., CHEN, L.S., HSU, Z., REYNA, J., CATON, J. and BRINGAS, P. (2006). Amelogenin and ameloblastin show growth-factor like activity in periodontal ligament cells. *Eur J Oral Sci* 114 Suppl 1: 244-53; discussion 254-6, 381-2.
- ZEICHNER-DAVID, M., VO, H., TAN, H., DIEKWISCH, T., BERMAN, B., THIEMANN, F., ALCOCER, M.D., HSU, P., WANG, T., EYNA, J. *et al.* (1997). Timing of the expression of enamel gene products during mouse tooth development. *Int J Dev Biol* 41: 27-38.
- ZOU, Y., WANG, H., SHAPIRO, J.L., OKAMOTO, C.T., BROOKES, S.J., LYGSTADAAS, S.P., SNEAD, M.L. and PAINE, M.L. (2007). Determination of protein regions responsible for interactions of amelogenin with cd63 and lamp1. *Biochem J* 408: 347-54.